2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Illumina, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #289 · 因美納公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | ILMN |
| Company | Illumina, Inc. |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #289 · 0.05% (Nov 3, 2026) |
| Sector rank | #36 of 60 in Health Care (Nov 3, 2026) |
| Headquarters | San Diego, California |
| Founded | 1998 |
| CEO | Jacob Thaysen (Chief Executive Officer) |
| Employees | 8,600 full-time (2025) |
| Market cap | $36.24B (Nov 3, 2026) |
| Share price | $238.94 (Nov 3, 2026) |
| SEC filings | EDGAR — CIK 0001110803 |
WHAT IT DOES
Illumina, Inc. is the world's leading maker of DNA sequencing systems, headquartered in San Diego, California. Its sequencers, consumables and analysis software are the default platform for genomic research and, increasingly, for clinical testing in oncology, reproductive health and rare disease.
Its one-line model: sell sequencing instruments into laboratories, then earn recurring high-margin revenue from the proprietary consumables each instrument consumes — in fiscal 2025 consumables were $3.23B of $4.34B total revenue (about 74%), against $482M of instruments and $634M of service and other revenue.
Illumina reports a single segment, Core Illumina, after spinning off its GRAIL cancer-detection unit in June 2024. Fiscal 2025 revenue was $4.34B, roughly flat against $4.37B a year earlier, and the company returned to profit — net income of $850M after a fiscal 2024 net loss of $1.22B that was driven largely by GRAIL-related charges.
BUSINESS SEGMENTS
| Consumables | Sequencing consumables — flow cells, reagents and kits consumed by the installed base — fiscal 2025 revenue of $3,227M, about 74% of the total and the recurring core of the model. |
| Instruments | Sequencing systems including the NovaSeq X series and mid-throughput instruments — fiscal 2025 revenue of $482M. |
| Service and other | Instrument service contracts, training and other services — fiscal 2025 revenue of $634M. |
HISTORY
| Year | Milestone |
|---|---|
| 1998 | Illumina is founded in San Diego, California, built initially around bead-array technology. |
| 2000 | Illumina lists on Nasdaq in its initial public offering. |
| 2007 | Illumina acquires Solexa for about $600M, gaining sequencing-by-synthesis technology — the foundation of its modern sequencing business. |
| 2014 | The HiSeq X Ten launches, marketed as the first $1,000-genome system. |
| 2017 | The NovaSeq series launches, extending high-throughput sequencing; the NovaSeq X follows in 2022. |
| 2021 | Illumina closes its roughly $8B acquisition of GRAIL in August 2021 despite U.S. and EU antitrust objections. |
| 2023 | Jacob Thaysen becomes chief executive in September 2023. |
| 2024 | After regulators order divestiture, Illumina spins off GRAIL to shareholders on June 24, 2024, retaining a minority stake. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $4.34B (FY2025 revenue) |
| Operating income | $807M (FY2025 operating income) |
| Net income | $850M (FY2025 net income) |
| Diluted EPS | $5.45 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Illumina is a small-weight health-care constituent: rank #289 by weight at 0.05% as of Nov 3, 2026, and #36 in Health Care. As the index's dominant genomics-sequencing platform, it is the cleanest listed read on global sequencing adoption in research and clinical settings.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Illumina, Inc. fiscal 2025 Form 10-K data via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and employees via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 3, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $36.24B (Slickcharts, Nov 3, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | ILMN |
| 公司 | Illumina, Inc.(因美納) |
| GICS 板塊/行業 | 醫療保健(XLV)/生命科學工具與服務 |
| 標普500排名(按權重) | #289 · 0.05%(Nov 3, 2026) |
| 板塊內排名 | 醫療保健 #36(共 60 家)(Nov 3, 2026) |
| 總部 | 美國加利福尼亞州聖迭戈 |
| 成立 | 1998年 |
| 執行長 | Jacob Thaysen(執行長) |
| 員工 | 8,600 名全職(2025年) |
| 市值 | $36.24B(Nov 3, 2026) |
| 股價 | $238.94(Nov 3, 2026) |
| SEC 申報 | EDGAR — CIK 0001110803 |
業務概覽
因美納是全球領先的 DNA 測序系統製造商,總部位於美國加利福尼亞州聖迭戈。其測序儀、耗材與分析軟件是基因組學研究的預設平台,並日益用於腫瘤、生殖健康與罕見病的臨床檢測。
其一句話商業模式是:向實驗室出售測序儀,再從每台儀器消耗的專有耗材賺取經常性高毛利收入——2025 財年耗材收入 32.27 億美元,佔總收入 43.43 億美元約 74%,儀器收入 4.82 億美元,服務及其他收入 6.34 億美元。
因美納於 2024 年 6 月分拆癌症檢測部門 GRAIL 後,只設一個報告板塊(Core Illumina)。2025 財年收入 43.43 億美元,與上年 43.72 億美元大致持平,公司重回盈利——淨利潤 8.50 億美元,而 2024 財年淨虧損 12.23 億美元,主要源於 GRAIL 相關費用。
業務板塊
| 耗材 | 測序耗材——裝機基礎消耗的流動槽、試劑與套裝——2025 財年收入 32.27 億美元,約佔總收入 74%,是商業模式的經常性核心。 |
| 儀器 | 測序系統,包括 NovaSeq X 系列及中通量儀器——2025 財年收入 4.82 億美元。 |
| 服務及其他 | 儀器服務合約、培訓及其他服務——2025 財年收入 6.34 億美元。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1998 | 因美納於加利福尼亞州聖迭戈成立,最初以微珠陣列技術為基礎。 |
| 2000 | 因美納在納斯達克首次公開招股上市。 |
| 2007 | 因美納以約 6 億美元收購 Solexa,取得邊合成邊測序技術——其現代測序業務的基礎。 |
| 2014 | HiSeq X Ten 推出,宣傳為首個「1,000 美元基因組」系統。 |
| 2017 | NovaSeq 系列推出,擴展高通量測序;NovaSeq X 於 2022 年跟隨推出。 |
| 2021 | 因美納於 2021 年 8 月完成約 80 億美元的 GRAIL 收購,儘管美國與歐盟反壟斷機構反對。 |
| 2023 | Jacob Thaysen 於 2023 年 9 月出任執行長。 |
| 2024 | 監管機構命令剝離後,因美納於 2024 年 6 月 24 日將 GRAIL 分拆予股東,保留少數股權。 |
競爭地位
財務快照
| 總收入 | $4.34B(FY2025 收入) |
| 營業利潤 | $807M(FY2025 營業利潤) |
| 淨利潤 | $850M(FY2025 淨利潤) |
| 稀釋 EPS | $5.45(FY2025 稀釋 EPS) |
主要風險
對標普500的重要性
因美納是權重較小的醫療保健成分股:按權重排名 #289,權重 0.05%(以 2026 年 11 月 3 日為準),醫療保健板塊內排名 #36。作為指數中主導的基因組測序平台,它是觀察全球研究與臨床測序普及的最清晰上市指標。
來源與方法
| 財務、板塊、總部 | 因美納 2025 財年 Form 10-K 數據,經 SEC EDGAR(見財務快照附註);總部、執行長與員工經 Form 10-K 及維基百科公司資料 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 3, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $36.24B(Slickcharts,Nov 3, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 10:33 · updated 2026-11-14 23:35 · rev 7